According to an accompanying Comment, this study represents a novel therapeutic approach for optimising treatment for patients with EGFR-mutant NSCLC and "the increase in progression-free survival constitutes a new landmark in the treatment of patients with EGFR-mutant NSCLC.” It suggests that the study might well pave the way to move from EGFR tyrosine-kinase inhibitor monotherapy to combination therapy to improve outcomes in this setting. If the clinical benefit of this combination of therapies is further validated, additional research could be warranted to prevent occurrence of possible novel mechanisms of resistance to VEGF-targeted therapies.